Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24286669 | 0.86 | LRRK2 (0.43) | ABL1CYP11B1CYP11B2LRRK2PIM1 | |
| SCHEMBL1322438 | 0.79 | CYP11B1 (0.50) | CYP11B1CYP11B2USP7 | |
| SCHEMBL24286093 | 0.79 | PIM1 (0.37) | ABL1CYP11B1CYP11B2LRRK2PIM1 | |
| SCHEMBL24286580 | 0.77 | LRRK2 (0.56) | ABL1LRRK2 | |
| SCHEMBL24286636 | 0.75 | LRRK2 (0.55) | ABL1LRRK2TGFBR1USP7 | |
| SCHEMBL26604284 | 0.71 | ABL1 (0.73) | ABL1LRRK2 | |
| SCHEMBL24285885 | 0.71 | LRRK2 (0.41) | ABL1LRRK2PIM1SRCGSK3A | |
| SCHEMBL24285993 | 0.70 | LRRK2 (0.42) | ABL1LRRK2PIM1SRCTGFBR1 | |
| SCHEMBL24286131 | 0.70 | TGFBR1 (0.39) | ABL1LRRK2TGFBR1MAPK14 | |
| SCHEMBL24286250 | 0.70 | ABL1 (0.42) | ABL1LRRK2PIM1SRCGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | 1ST Biotherapeutics, Inc. (KR) | 2023-09-05 | — | — | US | disclosed |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | 1ST Biotherapeutics, Inc. (KR) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | NLRP3, NLRP1, KCNJ2 | ABL1 966/4885CYP11B1 934/4885CYP11B2 344/4885 |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | NLRP3, NLRP1, KCNJ2 | ABL1 966/4885CYP11B1 934/4885CYP11B2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.